Every 424B that Centessa Pharmaceuticals Plc (CNTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CNTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTA filings page.
Centessa Pharmaceuticals plc is registering an at-the-market offering of American Depositary Shares with an aggregate offering price of up to $250,000,000. The ADSs, each representing one ordinary share, will be sold from time to time through Leerink Partners LLC as sales agent on The Nasdaq Global Select Market under the symbol CNTA, with Leerink earning up to 3.0% of gross proceeds as commission. This is a primary offering, so Centessa will receive the net proceeds, which it plans to use, together with existing cash and investments, to fund development of its product candidates and for general corporate purposes. As context, Centessa had 134,421,149 ordinary shares outstanding as of September 30, 2025, and recently completed a separate underwritten offering that increased pro forma net tangible book value before giving effect to this ATM program.
Centessa Pharmaceuticals plc launched a primary offering of 11,627,907 ADSs at $21.50 per ADS, for gross proceeds of $250,000,000. Underwriting discounts total $15,000,000 ($1.29/ADS), delivering proceeds before expenses of $235,000,000; estimated net proceeds are approximately $234.4 million.
The underwriters have a 30‑day option to purchase up to 1,744,186 additional ADSs. The company plans to use proceeds, together with existing cash, cash equivalents and investments, to fund continued development of product candidates and for general corporate purposes. Delivery is expected on or about November 14, 2025 (T+2).
Shares outstanding were 134,421,149 ordinary shares as of September 30, 2025. The offering results in immediate dilution of $17.84 per ADS to new investors, with an as‑adjusted net tangible book value of $3.66 per ADS after the offering. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and following this offering the company expects funding into 2028. Company, executives and directors agreed to a 60‑day lock‑up; certain shareholders up to 10 trading days.
Centessa Pharmaceuticals (CNTA) launched a preliminary prospectus supplement for a primary offering of American Depositary Shares (ADSs) under its automatic shelf. The underwriters have a 30‑day option to purchase additional ADSs. ADSs trade on Nasdaq Global Select Market; the last reported sale price was $22.33 per ADS on November 10, 2025. Settlement is expected on a T+2 basis.
Centessa expects to use net proceeds, together with existing cash, for continued development of its product candidates and general corporate purposes. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and the company expects funding runway into 2028. Ordinary shares outstanding were 134,421,149 as of September 30, 2025.
Recent R&D updates include ORX750 Phase 2a data across narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with 55 participants completing dosing; ORX750 was generally well tolerated. In IH (2.0 mg, n=17), ORX750 improved mean sleep latency on the MWT (p=0.0213). ORX142 Phase 1 (89 volunteers) showed rapid onset, differentiated PK, and improvements on MWT, with patient studies planned.
The company, its executive officers and directors are subject to lock-up agreements (60 days), with certain shareholders subject to up to 10 trading days, subject to stated exceptions.